Concepedia

Douglas D. Fang

DD

21

Publications

1.4K

Citations

17

H-Index

2010

Active since

Affiliations

WuXi AppTec (China)(Current)

Pfizer (United States)

Sun Yat-sen University Cancer Center

Sun Yat-sen University

Novartis (China)

Douglas D. Fang is an author at WuXi AppTec (China) specializing in medicine, cell biology, and oncology.

ORCID

Top concepts

Publications per year

2010–2022

21

Publications

21

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED

Wei Qi, Kehao Zhao, Justin Gu et al. · Nature Chemical Biology · 2017 · 313 citations · Full text

, , +7

Expansion of CD133+ colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery

Douglas D. Fang, Y J Kim, C N Lee et al. · British Journal of Cancer · 2010 · 149 citations · Full text

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

Douglas D. Fang, Qiuqiong Tang, Yanhui Kong et al. · Journal for ImmunoTherapy of Cancer · 2019 · 146 citations · Full text

Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy

Ying Huang, Jeff Zhang, Zhengtian Yu et al. · Journal of Medicinal Chemistry · 2017 · 100 citations · Full text

HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib

Douglas D. Fang, Bin Zhang, Qingyang Gu et al. · Journal of Thoracic Oncology · 2014 · 95 citations · Full text

, , +4

Rows per page

1–5 of 21